The stock of Immunovant Inc (IMVT) has seen a 11.76% increase in the past week, with a -5.50% drop in the past month, and a -25.88% decrease in the past quarter. The volatility ratio for the week is 5.84%, and the volatility levels for the past 30 days are at 8.50% for IMVT. The simple moving average for the last 20 days is 7.86% for IMVT’s stock, with a simple moving average of -35.62% for the last 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Additionally, the 36-month beta value for IMVT is 0.76. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMVT is 68.32M and currently, short sellers hold a 30.49% ratio of that float. The average trading volume of IMVT on May 01, 2025 was 1.81M shares.
IMVT) stock’s latest price update
The stock price of Immunovant Inc (NASDAQ: IMVT) has jumped by 6.11 compared to previous close of 15.22. Despite this, the company has seen a gain of 11.76% in its stock price over the last five trading days. globenewswire.com reported 2025-04-21 that NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at -8.07% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.15% of loss for the given period.
Volatility was left at 8.50%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares surge +6.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.43% lower at present.
During the last 5 trading sessions, IMVT rose by +11.76%, which changed the moving average for the period of 200-days by -47.17% in comparison to the 20-day moving average, which settled at $14.97. In addition, Immunovant Inc saw -34.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Stout Jay S, who sale 1,925 shares at the price of $14.79 back on Apr 23 ’25. After this action, Stout Jay S now owns 209,243 shares of Immunovant Inc, valued at $28,471 using the latest closing price.
Geffner Michael, the Chief Medical Officer of Immunovant Inc, sale 2,349 shares at $14.79 during a trade that took place back on Apr 23 ’25, which means that Geffner Michael is holding 225,370 shares at $34,742 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -270.14 for the present operating margin
- 0.9 for the gross margin
The net margin for Immunovant Inc stands at -255.14. The total capital return value is set at -1.15. Equity return is now at value -74.17, with -67.59 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -14127.65.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 1579.06. The receivables turnover for the company is 0.67for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.04.
Conclusion
In conclusion, Immunovant Inc (IMVT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
